1996 Fiscal Year Final Research Report Summary
Clinical Study of Immunotherapy at Pre-, Peri- and Psot-operation Applied ATK Activity to Lung Cancer
| Project/Area Number |
07671462
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Thoracic surgery
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
KATO Hirofumi Shiga Univ.of Med.Sci., 2nd Surgery Assist.Prof., 医学部, 講師 (20111974)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TEZUKA Noriaki Shiga Univ.of Med.Sci., 2nd Surgery Assist.Prof., 医学部, 医員
OKADA Yosio Shiga Univ.of Med.Sci., 2nd Surgery Assist.Prof., 医学部, 学長 (10106825)
|
|---|
| Project Period (FY) |
1995 – 1996
|
| Keywords | Adoptive immunotherapy / MUC-1 / Cytotoxic T Lymphocyte / Lung Cancer / Synthetic Peptide |
|---|
| Research Abstract |
MUC-1 molecule is a mucin protein expressed on paticular cancer cell surface and thought to be an important tumor antigen. In this study we have attempted to induce cytotoxic T lymphocyte (CTL) using synthetic peptide of MUC-1 and analyzed the specificity for this molecyle.
Peripheral blood mononuclear cell (PBMC) from lung cancer patients or normal donors was pulsed with the peptide and cultured in the presence of IL-7. The cell were re-stimulated with peptide-pulsed and irradiated PBMC every one week and cultured in the presence of IL-7 and IL-2. The MUC-1 specific activity of the induced CTL was tested at the end of 4th cycle of re-stimulateion. COLs had a strong cytotoxic acitivity against MUC-1 expressing MLC and T47D,and this activity was not inhibited by adding cold K562 which was sensitive to natural killar cells. And a cytotoxic activity of the CTLs was observed against MUC-1 transfectant whereas few activity was against the wild cell (MUC-1 deficient cell). These data show that the CTLs are specific for MUC-1.
Clinical study of the adoptive immunotherapy was performed to 2 advanced lung cancer patients with the CTLs using MUC-1 peptide. Clinical symptons were improved and tumor maker (CEA) level was decreased on both patients administered the CTLs. And severe side effects were not observed.
This methods was thought tobe useful for the purpose of immunotherapy for lung cancer.
|
